The Food and Drug Administration (FDA) announced last week that it had extended the deadline for input on its draft guidance outlining approaches for demonstrating the effectiveness of new drugs, InsideHealthPolicy reports.
The deadline has been extended to March 19 this year.
According to the report, the timeframe was changed following requests from multiple lobbies.
To read the full report on InsideHealthPolicy, click here.
